185225-82-5Relevant academic research and scientific papers
JAK kinase inhibitor and application thereof
-
Sheet 0152-0157, (2020/11/23)
The invention discloses a JAK kinase inhibitor and an application thereof. The JAK kinase inhibitor is a compound represented by a formula I or a stereoisomer, a tautomer or pharmaceutically acceptable salt or a solvate or a prodrug of the compound; the invention further provides the application of the compound represented by the formula I in preparation of drugs for preventing or treating JAK kinase related diseases, and in particular, relates to the application in preparing medicines for preventing and/or treating diseases related to cartilage degeneration and bone and/or joint degeneration,diseases related to inflammation or immune response, endotoxin-driven disease states, cancers and organ transplantation rejection.
INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Page/Page column 44; 45, (2020/11/30)
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER
-
Paragraph 0270-0271, (2020/05/12)
Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods
BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF
-
Paragraph 0632-0634, (2019/05/15)
The invention provides novel compounds having the general formula I: wherein R1, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of usi
5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT
-
Paragraph 0311-0312, (2019/01/11)
Provided is a compound which is useful as an AMPK activator. A compound represented by formula: wherein X is substituted or unsubstituted monocyclic heterocyclyl or the like; ring A is substituted aryl, substituted heteroaryl, substituted cycloalkyl, substituted cycloalkenyl, or substituted heterocyclyl, wherein the ring A may further have a substituent(s) other than Y; Y is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like; R4, R5, R6 and R7 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted acyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, or substituted or unsubstituted amino; R8 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like; and R9 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like, or its pharmaceutically acceptable salt.
NAPHTHYRIDINES AS INHIBITORS OF HPK1
-
Paragraph 0608; 0609, (2018/10/21)
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
ISOQUINOLINES AS INHIBITORS OF HPK1
-
Paragraph 0493; 0494, (2018/10/21)
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
